Evidence map›Paper›PMID 41854856›Full record

ArticleJournal of applied clinical medical physics2026

Post hoc estimation of a quantitative restriction spectrum imaging biomarker for prostate cancer detection using conventional MRI.

Deondre D Do, Christopher C Conlin, Aditya Bagrodia, Matthew Cooperberg, Michael E Hahn, Mukesh Harisinghani, Gary Hollenberg, Juan Javier-Desloges, Sophia C Kamran, Christopher J Kane and 18 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Deondre D DoDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0009-0007-5943-3379
Christopher C ConlinDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Aditya BagrodiaDepartment of Urology, University of California San Diego, La Jolla, California, USA.
Matthew CooperbergDepartment of Urology, University of California San Francisco, San Francisco, California, USA.
Michael E HahnDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Mukesh HarisinghaniDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gary HollenbergDepartment of Imaging Sciences, University of Rochester Medical Center, Rochester, New York, USA.
Juan Javier-DeslogesDepartment of Urology, University of California San Diego, La Jolla, California, USA.
Sophia C KamranDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Christopher J KaneDepartment of Urology, University of California San Diego, La Jolla, California, USA.
Kang-Lung LeeDepartment of Radiology, University of Cambridge, Cambridge, UK.
Michael A LissDepartment of Urology, University of California San Diego, La Jolla, California, USA.
Daniel J A MargolisDepartment of Radiology, Weill Cornell Medical College, New York, New York, USA.
Paul M MurphyDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Nabih NakrourDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael A OhligerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
Thomas OsinskiDepartment of Urology, University of Rochester Medical Center, Rochester, New York, USA.
Rebecca Rakow-PennerDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Mariluz Rojo DomingoDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.
Amirali SalmasiDepartment of Urology, University of California San Diego, La Jolla, California, USA.
Ahmed S ShabaikDepartment of Pathology, University of California San Diego, La Jolla, California, USA.
Yuze SongDepartment of Radiation Medicine, University of California San Diego, La Jolla, California, USA.
Shaun TrecartenDepartment of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, Texas, USA.
Natasha WehrliDepartment of Radiology, Weill Cornell Medical College, New York, New York, USA.
Eric P WeinbergDepartment of Imaging Sciences, University of Rochester Medical Center, Rochester, New York, USA.
Sean WoolenDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
Anders M DaleDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Tyler M SeibertDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.

Funding

NIH HHS NIH UL1TR000100Prostate Cancer Foundation 24CHAL05U.S. Department of Defense DOD/CDMRP PC220278
6 · The paper itself

Abstract

backgroundMultiparametric MRI is useful for early detection of clinically significant prostate cancer (csPCa), but its standard apparent diffusion coefficient (ADC) has limited utility as a quantitative metric for automated, patient-level detection of csPCa. Restriction spectrum imaging (RSI), an advanced diffusion technique, yields a quantitative biomarker (RSIrs) that improves csPCa detection. RSIrs is typically calculated from a dedicated multi-b-value acquisition. RSIrs estimated from conventional MRI has not been studied. PURPOSE: To evaluate the accuracy and validity of RSI metrics estimated post hoc from conventional diffusion-weighted imaging (DWI) to serve as a viable surrogate for a dedicated RSI acquisition. MATERIALS AND

methodsWe conducted a retrospective, multicenter study of patients with both a dedicated RSI acquisition and conventional DWI. We compared three different RSI restriction score (RSIrs) calculation methods: from the dedicated acquisition (RSIrs

resultsData from n = 1095 patients (16 centers) were analyzed. Post hoc RSIrs

conclusionEven when estimated using conventional DWI, RSIrs is a superior quantitative biomarker to ADC for automated, patient-level detection of csPCa. A dedicated RSI acquisition gives the best performance. A compromise would be to acquire high b-values (1500 and 2500 s/mm

Indexed as

Biomarkers, TumorDiffusion Magnetic Resonance ImagingImage Interpretation, Computer-AssistedImage Processing, Computer-AssistedMagnetic Resonance ImagingProstatic NeoplasmsAgedAlgorithmsHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingPrognosisRetrospective StudiesROC CurveBiomarkers, Tumordiffusion weighted imagingprostate cancerradiation therapyrestriction spectrum imaging

Identifiers

PMID41854856
PMCPMC13093628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.